Condition
Hyperphagia in Prader-Willi Syndrome
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (3)
Trial Status
Active Not Recruiting1
Completed1
Enrolling By Invitation1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07197034Phase 3Terminated
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
NCT06420297Phase 3Enrolling By InvitationPrimary
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT06173531Phase 3Active Not RecruitingPrimary
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
NCT01968187Phase 2CompletedPrimary
Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
Showing all 4 trials